CLINICAL EXPERIENCE WITH PIPOTIAZINE PALMITATE (19.552 R.P.) IN NORDIC COUNTRIES: Report of a multicentre investigation

Preliminary experience of 19.552 R.P. (the palmitate ester of pipotiazine) and of its parent compound 19.366 R.P., has given evidence of the potent neuroleptic properties of these compounds and an indication of a more prolonged action of 19.552 R.P. than of any other long-acting phenothiazines. At a preliminary meeting organized by Pharma Rhodia, Denmark, at Elsinore in August 1970, clinicians from four Nordic countries agreed to participate in a joint investigation of the clinical properties and side-effects of 19.552 R.P., employing a fixed scheme agreed upon in advance.